
World Drug Safety Congress: Drug Therapy for Spinal Stenosis

V Lunde Dadon*

Unilabs Biomedical Research Institute L.P.

*Corresponding author: V Lunde Dadon, Unilabs Biomedical Research Institute L.P, Outlying Islands.

E-mail: mllcsage808@gmail.com

Received: July 14, 2024; **Accepted:** July 26, 2024; **Published:** August 15, 2024

Abstract

1. Solutions: Pharmacology intervention for Drug Therapy adherence Spinal Stenosis
2. Studies, programmed encounter with pharmacology slides in lab
3. Summary of findings
4. Design of laboratory and pharmacology experimentation
5. Participants in material science engineering of (MicroCell Clones)
6. Microsoft Office 4 year submit recordings findings, of clinical trials
7. Results, Thesis for further examination
8. Wider (earthly) limitations, implied funding
9. Findings, procedure outlined, Trial Registration by verbal dissertation, methodology, scaling words, explanation.

Unilabs employees pathology and pharmacology report on findings for cloning stem cells using Global Pharmaceuticals Regulatory actions to enhance research in Spinal Stenosis.

Stem cells can be harvested from patients body or donor injected in LSCS through Dissectomy. Stems cells can differentiate, under microphage, and micro- recoperative stages. We performed this pharmacology procedure under Phase I, Phase II, and Phase III.

Goal was to repair damaged tissues bone, cartilage, nerves (CNS).

Epidemiologist, Pathologist, imaging specialist worked on the (IVD) portions. Pharmacist concluded in the DOI Trial Registrations clinical trial a combo of the ultrapurified allogenic bone-marrow, derive from mesenchymal cells into the (IVD) by Pharmacology Experts. Defective (IVD) testing lead to predispose patents. Osteopathic specialist alongside Pharmacologists initiated pathology testing to discovery after the dura mater and nerve roots were remarkable after laminoplasty surgeries. Not so much.

Design laboratory rapidly submitted ultrapurified stems cells expanding in 20-Micro Cell clones (REC). Bioreservorbablige (dMD-001) to full (IVD) deflected with drug combo REC and dMD-001 them implanted into the (IVD) on video, live presentation and forms on Microsoft 365 Access through institutions capture.

Finding is proposed for future MRI based scores of morphological and composited quality after pharmacologic testing results in quality of the IVD tissue, for procurement of Spinal Stenosis diagnoses.

Limitation of the conclusions of the diagnosis of spinal stenosis results in a gap of time, and roundtable discussions to promote funding.